Marie-Claude Lavallée

Energy and integrated dose dependence of MOSFET dosimeter sensitivity for irradiation energies between 30 kV and 60Co.

Since metal-oxide-semiconductor field effect transistors (MOSFETs) medical applications in radiotherapy and radiology are gaining popularity, evaluating them under radiation of different energies is of major interest. This study aims at a characterization of MOSFET sensitivity with regard to total integrated dose. Sensitivity is expressed by the water calibration factor (CFw) and allows the user to associate the voltage difference reading displayed by the device to a dose value in water at the MOSFET location. The CFw of seven p-type dual-bias MOSFETs were measured for several accumulated doses. The radiation sources used were a Co60 unit (⟨E⟩γ:1.25MeV), an Ir192 high dose rate unit (⟨E⟩γ:380keV), and an orthovoltage unit providing two x-ray energy spectra for tube voltages of 30kV(⟨E⟩γ:14.8KeV) and 150kV(⟨E⟩γ:70.1keV). The CFw value diminishes with increasing threshold voltage, especially for low-energy radiation. It was stable for Co60 irradiations, while it decreased 6%, 5%, and 15% for beam energies of Ir192, 150kV, and 30kV, respectively. The decrease rate is higher for the first half of the device lifetime. This behavior is explained by an alteration of the effective electric field applied to the MOSFET during irradiation, caused by the accumulation of holes at the Si-SiO2 interface. It is strongly dependent on the nature of the radiation, and particularly affects low x-ray energies. A frequent calibration of the device for this radiation type is essential in order to achieve adequate measurement accuracy, especially in low-energy applications, such as superficial therapy, brachytherapy, and diagnostic and interventional radiology.

Prostatic edema in 125I permanent prostate implants : Dynamical dosimetry taking volume changes into account

The purpose of this study is to determine the impact of edema on the dose delivered to the target volume. An evaluation of the edema characteristics was first made, and then a dynamical dosimetry algorithm was developed and used to compare its results to a standard clinical (static) dosimetry. Source positions and prostate contours extracted from 66 clinical cases on images taken at different points in time (planning, implant day, post-implant evaluation) were used, via the mean interseed distance, to characterize edema [initial increase (deltar0), half-life (tau)]. An algorithm was developed to take into account the edema by summing a time series of dose-volume histograms (DVHs) with a weight based on the fraction of the dose delivered during the time interval considered. The algorithm was then used to evaluate the impact of edema on the dosimetry of permanent implants by comparing its results to those of a standard clinical dosimetry. The volumetric study yielded results as follows: the initial prostate volume increase was found to be 1.58 (ranging from 1.15 to 2.48) and the edema half-life, approximately 30 days (range: 3 to 170 days). The dosimetric differences in D90 observed between the dynamic dosimetry and the clinical one for a single case were up to 15 Gy and depended on the edema half-life and the initial volume increase. The average edema half-life, 30 days, is about 3 times longer than the previously reported 9 days. Dosimetric differences up to 10% of the prescription dose are observed, which can lead to differences in the quality assertion of an implant. The study of individual patient edema resorption with time might be necessary to extract meaningful clinical correlation or biological parameters in permanent implants.

Inverse-planned gynecologic high-dose-rate interstitial brachytherapy: Clinical outcomes and dose–volume histogram analysis

PURPOSE To present clinical outcomes and dose-volume histogram parameters of three-dimensional image-based high-dose-rate interstitial brachytherapy (HDR-ISBT) in patients with primary or recurrent gynecologic cancer unsuitable for intracavitary brachytherapy (ICB). METHODS AND MATERIALS Records of 43 women treated between 2001 and 2009 with iridium-192 gynecologic HDR-ISBT boost, using a Syed-Neblett template and inverse planning simulated annealing dose optimization, were reviewed. Median HDR-ISBT dose was 30Gy, delivered in 4-6Gy/fraction. Dose-volume histogram parameters recommended by the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology for image-based ICB were analyzed. Total doses were normalized to 2Gy fractions (biologically equivalent dose in 2Gy fractions). Local control (LC) and survival were calculated using Kaplan-Meier method. Toxicities were defined according to Common Terminology Criteria for Adverse Events v3.0. RESULTS There were 34 primary malignancies (cervix=12, vagina=15, Bartholins gland=5, and vulva=2) and 9 recurrences. International Federation of Gynecology and Obstetrics stage distribution for primary cancers was I=2, II=13, III=15, and IV=4. Median followup was 19.3 months (range, 0-92.2). Two-year LC was 87% for primary cancers, and 45% for recurrent cancers, respectively (p=0.0175). Median V(100), D(90), and D(100) for clinical target volume were 97.6%, 90.2, and 68.7Gy(10), respectively. Median bladder and rectal D(2)(cc) were 76.6 and 79.5Gy(3), respectively. Median urethral D(10) was 80.6Gy(3). Twelve patients experienced Grades 3 and 4 late morbidity, but toxicities were transient. Only 2 patients had persistent severe toxicities. A trend toward increased risk for vaginal necrosis was observed with a clinical target volume >84cc. CONCLUSIONS HDR-ISBT may achieve good LC in gynecologic cancer unsuitable for ICB, especially in primary malignancies with a 2-year LC rate higher than 85%. Delivery of such high doses has potential advantages but may predispose to adverse effects, reversible in most cases.

Validation of the Oncentra Brachy Advanced Collapsed cone Engine for a commercial 192Ir source using heterogeneous geometries

PURPOSE To validate the Advanced Collapsed cone Engine (ACE) dose calculation engine of Oncentra Brachy (OcB) treatment planning system using an (192)Ir source. METHODS AND MATERIALS Two levels of validation were performed, conformant to the model-based dose calculation algorithm commissioning guidelines of American Association of Physicists in Medicine TG-186 report. Level 1 uses all-water phantoms, and the validation is against TG-43 methodology. Level 2 uses real-patient cases, and the validation is against Monte Carlo (MC) simulations. For each case, the ACE and TG-43 calculations were performed in the OcB treatment planning system. ALGEBRA MC system was used to perform MC simulations. RESULTS In Level 1, the ray effect depends on both accuracy mode and the number of dwell positions. The volume fraction with dose error ≥2% quickly reduces from 23% (13%) for a single dwell to 3% (2%) for eight dwell positions in the standard (high) accuracy mode. In Level 2, the 10% and higher isodose lines were observed overlapping between ACE (both standard and high-resolution modes) and MC. Major clinical indices (V100, V150, V200, D90, D50, and D2cc) were investigated and validated by MC. For example, among the Level 2 cases, the maximum deviation in V100 of ACE from MC is 2.75% but up to ~10% for TG-43. Similarly, the maximum deviation in D90 is 0.14 Gy between ACE and MC but up to 0.24 Gy for TG-43. CONCLUSION ACE demonstrated good agreement with MC in most clinically relevant regions in the cases tested. Departure from MC is significant for specific situations but limited to low-dose (<10% isodose) regions.

Commissioning and evaluation of an extended SSD photon model for PINNACLE3: an application to total body irradiation.

Total body irradiations (TBIs) are unusual radiation therapy techniques used to treat specific hematological diseases. Most TBI techniques use extended source to patient distances [source-to-skin distance (SSD)] to provide lateral or anteroposterior irradiations. Those techniques differ from one institution to the other since they need to be customized to accommodate for local material constraints. However, with those unusual techniques come additional challenges for dose calculation. The purpose of this study was to obtain an accurate (better than 4%) dose calculation model for extended source-to-skin distance (eSSD) treatment techniques, which will be used for TBI planning. The studied dynamic TBI technique has special aspects (eSSD, beam spoiler, large field, and out of field dose contribution) that need to be considered in dose calculation. The first part of this study presents an eSSD beam model commissioning in PINNACLE3 and its validation. The second part looks at the comparison between two dose calculation algorithms, the 3D pencil beam and the superposition-convolution algorithms implemented in THERAPLAN PLUS and PINNACLE3 , respectively. A regular linac beam was commissioned in each treatment planning system and an additional dedicated TBI beam model was implemented in PINNACLE3 . The comparison results indicate that the quality of the TBI treatment greatly depends on the treatment planning system and its beam commissioning. The superposition-convolution algorithm (PINNACLE3 ) provides a better dose calculation tool for TBI than the 3D pencil beam algorithm (THERAPLAN PLUS) with a maximum mean error of 2.2% on a dynamic treatment. The TBI specific beam model of PINNACLE3 (ESSP-P3) also improves the dose calculation. The maximum difference between calculations and measurements (depth doses and beam profiles) was 2% except for extreme cases (build-up region and depth of 20cm) where the error was higher. Output factor determination and the dose contribution outside the primary beam weaknesses were found in PINNACLE3 . Methods are proposed to overcome these limitations. With the correction method applied, the TBI specific beam model allows a maximum mean error of -0.68% on a dynamic treatment. Accurate TBI dose computation necessitates a good dose calculation algorithm combined with a realistic beam model. Inappropriate dose calculation could lead to an important over- or underdose estimation. No perfect algorithm and beam model were found, but methods are proposed to overcome some of the limitations. Those methods are simple and can be used for other eSSD treatment types.

Attenuator design for organs at risk in total body irradiation using a translation technique.

Total body irradiation (TBI) is an efficient part of the treatment for malignant hematological diseases. Dynamic TBI techniques provide great advantages (e.g., dose homogeneity, patient comfort) while overcoming treatment room space restrictions. However, with dynamic techniques come additional organs at risk (OAR) protection challenges. In most dynamic TBI techniques, lead attenuators are used to diminish the dose received by the OARs. The purpose of this study was to characterize the dose deposition under various shapes of attenuators in static and dynamic treatments. This characterization allows for the development of a correction method to improve attenuator design in dynamic treatments. The dose deposition under attenuators at different depths in dynamic treatment was compared with the static situation based on two definitions: the coverage areas and the penumbra regions. The coverage area decreases with depth in dynamic treatment while it is stable for the static situation. The penumbra increases with depth in both treatment modes, but the increasing rate is higher in the dynamic situation. Since the attenuator coverage is deficient in the dynamic treatment mode, a correction method was developed to modify the attenuator design in order to improve the OAR protection. The correction method is divided in two steps. The first step is based on the use of elongation charts, which provide appropriate attenuator coverage and acceptable penumbra for a specific depth. The second point is a correction method for the thoracic inclination, which can introduce an orientation problem in both static and dynamic treatments. This two steps correction method is simple to use and personalized to each patients anatomy. It can easily be adapted to any dynamic TBI techniques.

Monte Carlo dosimetry of high dose rate gynecologic interstitial brachytherapy.

PURPOSE To assess the dosimetric effects of the presence of the applicator, air pockets in clinical target volume (CTV) and OARs along with tissue heterogeneities using the Monte Carlo (MC) method in high dose rate (HDR) gynecologic interstitial brachytherapy with a Syed-Neblett template. METHODS AND MATERIALS The CT based dosimetry has been achieved with the Geant4 MC toolkit version 9.2. DICOM-RT files of 38 patients were imported into our own platform for MC simulations. The dose distributions were then compared to those obtained with a conventional TG-43 calculation. RESULTS Taking account of heterogeneities has effects of the order of 1% on the HDR gynecological dose distributions. However, the exclusion of air pockets and applicator from the DVH calculation can lower the CTV D90 and V100 by as much as 8.7% and 5.0% in comparison with TG-43. Rectum dosimetric indices can also be lowered by approximately 3% compared with TG-43 for most cases. Differences for urethra and bladder are for most cases below 1%. CONCLUSIONS Exclusion of non-biological material such as air pockets and applicator volume from the CTV is important for both TG-43 and MC calculations. It could be easily implemented and automated in treatment planning systems without affecting computation times.

3D heterogeneous dose distributions for total body irradiation patients

One major objective of total body irradiation (TBI) treatments is to deliver a uniform dose in the entire body of the patient. Looking at 3D dose distributions for constant speed (CstSpeed) and variable speed (VarSpeed) translating couch TBI treatments, dose uniformity and the effect of body heterogeneities were evaluated. This study was based on retrospective dose calculations of 10 patients treated with a translating couch TBI technique. Dose distributions for CstSpeed and VarSpeed TBI treatments have been computed with Pinnacle 3 treatment planning system in homogeneous (Homo) and heterogeneous (Hetero) dose calculation modes. A specific beam model was implemented in Pinnacle 3 to allow an accurate dose calculation adapted for TBI special aspects. Better dose coverages were obtained with Homo/VarSpeed treatments compared to Homo/CstSpeed cases including smaller overdosage areas. Large differences between CstSpeed and VarSpeed dose calculations were observed in the brain, spleen, arms, legs, and lateral parts of the abdomen (differences between V100% mean values up to 57.5%). Results also showed that dose distributions for patients treated with CstSpeed TBI greatly depend on the patient morphology, especially for pediatric and overweight cases. Looking at heterogeneous dose calculations, underdosages (2%–5%) were found in high‐density regions (e.g., bones), while overdosages (5%–15%) were found in low‐density regions (e.g., lungs). Overall, Homo/CstSpeed and Hetero/VarSpeed dose distributions showed more hot spots than Homo/VarSpeed and were greatly dependent on patient anatomy. CstSpeed TBI treatments allow a simple optimization process but lead to less dose uniformity due to the patient anatomy. VarSpeed TBI treatments require more complex dose optimization, but lead to a better dose uniformity independent of the patient morphology. Finally, this study showed that heterogeneities should be considered in dose calculations in order to obtain a better optimization and, therefore, to improve dose uniformity. PACS number: 87.55.D

High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes

PURPOSE To report the outcomes of our high-dose-rate brachytherapy (HDR-BT) boost experience in localized prostate cancer treated with different combinations of radiation doses and fractionation. MATERIAL AND METHODS Between 1999 and 2011, 832 patients were treated with different regimens of external beam radiotherapy (EBRT) and HDR-BT. These regimens were converted into three biologically effective dose (BED) groups. The biochemical failure-free survival (BFFS), reported with the phoenix definition and prostate-specific antigen (PSA) >0.2ng/ml at 5-year, genitourinary (GU) and gastrointestinal (GI) toxicities were compared between the groups. RESULTS The 5-, 10-year BFFS for the entire cohort were 94.6% and 92.5%, for overall survival (OS) 96.1% and 80.3% and for prostate cancer-specific survival (PCSS) 99.5% and 97.8%. The percentage of patients with a 5-year PSA level <0.2ng/ml was 68.6%, 78.7% and 86.7% in the BED group of <250, 250-260 and >260Gy (p=0.005) while the 5-year BFFS rates according to phoenix definition were 97.3%, 94.3% and 94.9% for BED group <250, 250-260 and >260Gy (p=0.453). On multivariate logistic regression, patients in the BED>260Gy group were significantly more likely to remain free from 5-year PSA values ≥0.2ng/mL compared with those in the BED<250Gy group (OR: 0.350, p=0.011). Grade≥3 acute GU toxicity was reported in 2 patients (4.7%) for BED>260Gy while grade≥3 late GU toxicity was reported in 6 (1.7%) and 9 (4.9%) patients for 250-260Gy and >260Gy BED groups. CONCLUSIONS The increase in BED with the hypofractionated regimens correlates with an improvement in biochemical control with of urinary toxicity. This increase in urinary toxicity is small and clinically acceptable.

Management of Bartholin’s gland carcinoma using high-dose-rate interstitial brachytherapy boost

PURPOSE To describe the patterns of use, clinical outcomes, and dose-volume histogram parameters of high-dose-rate interstitial brachytherapy (HDR-ISBT) in the management of Bartholins gland cancer. METHODS AND MATERIALS Five patients with Stage II-III Bartholins gland carcinoma treated with CT-based HDR-ISBT boost were reviewed. Plans were generated using an inverse planning simulated annealing algorithm. Dose-volume histogram parameters were assessed. The total doses of HDR-ISBT and EBRT were converted to total equivalent dose in 2Gy (EQD2). RESULTS All 5 patients received HDR-ISBT as a boost (median dose, 30Gy) after EBRT (median dose, 45Gy). Three patients received postoperative irradiation for gross residual tumor or positive surgical margins and 2 patients were treated by primary chemoradiotherapy. The median V100, D90, and D100 for the CTV were 98.3%, 89Gy10, and 64Gy10 (EQD2), respectively. A complete response was observed in all patients. No local recurrence occurred. All patients remain alive and free of disease (median followup, 78 months; range, 8-93). Severe vaginal toxicities were observed, including vaginal necrosis that resolved with hyperbaric oxygen therapy. CONCLUSIONS HDR-ISBT boost after EBRT offers excellent long-term local control in patients with Bartholins gland carcinoma. HDR-ISBT should be considered for positive surgical margins or residual tumor after surgery and for locally advanced malignancies treated by primary chemoradiotherapy.